Xiaomin Xiong
Overview
Explore the profile of Xiaomin Xiong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
83
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lei D, Zhang Y, Wang H, Xiong X, Xu B, Wang G
IEEE J Biomed Health Inform
. 2025 Mar;
PP.
PMID: 40030598
In many challenging breast cancer pathology images, the proportion of truly informative tumor regions is extremely limited. The disparity between the essential information required for clinical diagnosis (Tumor area less...
2.
Li S, Dai Z, Zhang T, Guo Z, Gao F, Cheng X, et al.
Front Pharmacol
. 2024 Nov;
15:1448069.
PMID: 39575390
Background: With a growing global population affected by Chronic Obstructive Pulmonary Disease (COPD), the traditional Chinese herbal formula Houpo Mahuang Decoction (HPMHD) has been used for centuries to address respiratory...
3.
Li Y, Xiong X, Liu X, Wu Y, Li X, Liu B, et al.
PeerJ
. 2024 Nov;
12:e18098.
PMID: 39484212
Background: Determining the status of breast cancer susceptibility genes () is crucial for guiding breast cancer treatment. Nevertheless, the need for genetic testing among breast cancer patients remains unmet due...
4.
Li M, Xiong X, Xu B
Front Digit Health
. 2024 Sep;
6:1371302.
PMID: 39290363
Background: Artificial intelligence (AI) is transforming healthcare, yet little is known about Chinese oncologists' attitudes towards AI. This study investigated oncologists' knowledge, perceptions, and acceptance of AI in China. Methods:...
5.
Li Y, Xiong X, Liu X, Xu M, Yang B, Li X, et al.
Ann Med
. 2024 Sep;
56(1):2399759.
PMID: 39258876
Background: The status of genes plays a crucial role in the treatment decision-making process for multiple cancer types. However, due to high costs and limited resources, a demand for genetic...
6.
Li S, An J, Zhang T, Chen G, Zhang Z, Guo Z, et al.
J Ethnopharmacol
. 2024 Aug;
336:118759.
PMID: 39209003
Ethnopharmacological Relevance: Hypercholesterolemia (HLC) was a key risk factor for cardiovascular disease (CVD) characterized by elevated cholesterol levels, particularly LDL. While traditional Chinese medicine preparations Compound Danshen Pills(CDP) has been...
7.
Li M, Xiong X, Xu B, Dickson C
JMIR Form Res
. 2024 Jun;
8:e53918.
PMID: 38838307
Background: The rapid development of artificial intelligence (AI) has brought significant interest to its potential applications in oncology. Although AI-powered tools are already being implemented in some Chinese hospitals, their...
8.
Wu Y, Li Y, Xiong X, Liu X, Lin B, Xu B
Front Oncol
. 2023 Aug;
13:1094869.
PMID: 37538112
Colorectal cancer (CRC) is one of the most common malignancies, with the third highest incidence and the second highest mortality in the world. To improve the therapeutic outcome, the risk...
9.
Wu Y, Liu X, Liu F, Li Y, Xiong X, Sun H, et al.
PeerJ
. 2023 Jun;
11:e15408.
PMID: 37334122
Neoadjuvant therapy (NAT) is a major treatment option for locally advanced rectal cancer. With recent advancement of machine/deep learning algorithms, predicting the treatment response of NAT has become possible using...
10.
Li S, Wang Y, Zhang X, Xiong X, Zhou F, Li X, et al.
Metabolomics
. 2023 Jun;
19(6):56.
PMID: 37289288
Introduction: Accumulation of β-amyloid (Aβ) in neurons of patients with Alzheimer's disease (AD) inhibits the activity of key enzymes in mitochondrial metabolic pathways, triggering mitochondrial dysfunction, which plays an important...